pharmaphorum
NOVEMBER 28, 2021
The three-year phase 2 trial will be carried out by researchers at Leeds University led by professor of clinical oncology and neuro-oncology Susan Short, and see if adding Sativex (nabiximols) to standard chemotherapy for recurrent glioblastoma can extend survival. Jazz acquired rights to Sativex when it completed its $7.2
Blog: Ask a Student Pharmacist
JUNE 21, 2023
Antimicrobial agents and chemotherapy. Antimicrobial agents and chemotherapy. Antiviral chemistry & chemotherapy. 2009; 1(7):1233-41. 2009; 19(14):3804-7. 2009; 10(9):1519-26. 2009; 20(3):410-4. 5-Azacytidine Enhances the Mutagenesis of HIV-1 by Reduction to 5-Aza-2'-Deoxycytidine. Retrovirology.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Checkup by Singlecare
DECEMBER 13, 2023
Antiemetics may also reduce radiation-associated or chemotherapy-induced nausea resulting from cancer treatment. Certain antihistamines work as antiemetics by blocking histamine from binding to receptors in the area of the brain that cause unpleasant symptoms.
The Checkup by Singlecare
JANUARY 10, 2024
According to one study , topical vitamin E helped treat oral mucositis —the swelling or irritation of tissues inside the mouth– in patients who were undergoing chemotherapy. Vitamin E Vitamin E is known for contributing to healthy skin.
NF2 BioSolutions
DECEMBER 18, 2023
” B: “Hair thinning (Avastin is not the type of chemotherapy at the dose NF2ers have it to cause hair loss, however several people do mention hair thinning or fuzziness).” So it’s likely avastin has caused this dysfunction. Thankfully it’s very mild and not causing me issues.
The Thyroid Pharmacist
SEPTEMBER 20, 2024
Chemotherapy agents: Chemotherapy agents can lead to constipation in a variety of ways such as slowing the movements of the intestinal tract or creating inflammation that disrupts digestive function. doi:10.1155/2009/529802 [7] Patel KS, Thavamani A. 2013;122(1):218-238. doi: 10.1053/j.gastro.2012.10.028. 2012.10.028. [6]
Pharmaceutical Technology
JUNE 23, 2022
The treatment is intended for patients with NSCLC harbouring alterations leading to mesenchymal-epithelial-transition factor gene (MET) exon 14 (METex14) skipping and for those who need systemic therapy after previous treatment with immunotherapy and/or platinum-based chemotherapy. It was discovered by Incyte and licensed to Novartis in 2009.
Expert insights. Personalized for you.
136 
Let's personalize your content